Furthermore, human diseases mimicking Lmna−/− mice—muscular dystrophy and progeroid syndromes—targeted inhibition of S6K1 might be an effective therapeutic approach, whereas not as powerful as rapamycin but might limit associated immunosuppressive side effects. This evidence concerns the gene RPS6KB1 and muscular dystrophy.